Neonatal outcome of the pregnancies associated with placental villous thrombosis thrombophilic status of the mothers and the infants

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 25, Issue 11, 2012, Pages 2225-2229

  Demirel, Gamze ^a   Celik, Istemi Han ^a   Zergeroglu, Sema ^a   Erdeve, Omer ^a   Dilmen, Ugur ^a,b  

^a Zekai Tahir Burak Maternity Teaching Hospital   (Turkey)

^b YILDIRIM BEYAZIT UNIVERSITY   (Turkey)

Author keywords

Neonatal outcome; Placenta; Thrombophilic mutation; Villous thrombosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); APOLIPOPROTEIN B; APOLIPOPROTEIN E; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; DIPEPTIDYL CARBOXYPEPTIDASE; FIBRINOGEN; FIBRINOGEN B BETA CHAIN; HUMAN PLATELET ANTIGEN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONGENITAL MALFORMATION; DISEASE PREDISPOSITION; FEMALE; FETAL VASCULOPATHY; FETUS; FETUS WASTAGE; GENE MUTATION; HIGH RISK PREGNANCY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MASS SCREENING; NEWBORN; NEWBORN INTENSIVE CARE; NEWBORN MORTALITY; OUTCOME ASSESSMENT; PLACENTAL VILLOUS THROMBOSIS; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREMATURITY; PRIORITY JOURNAL; RISK FACTOR; STILLBIRTH; THROMBOPHILIA; THROMBOSIS; VASCULAR DISEASE;

ADULT; CHORIONIC VILLI; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; MALE; MOTHERS; PLACENTA DISEASES; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY OUTCOME; PROGNOSIS; PUERPERAL DISORDERS; THROMBOPHILIA; THROMBOSIS;

EID: 84867559010     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2012.684169     Document Type: Article

References (18)

1. Lanir N, Aharon A, Brenner B. Haemostatic mechanisms in human placenta. Best Pract Res Clin Haematol 2003;16:183-195.
2. Branch D W, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992;80:614-620.
3. Out HJ, Bruinse H W, Christiaens GC, van Vliet M, de Groot PG, Nieuwenhuis HK, Derksen RH. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol 1992;167:26-32.
4. Vora S, Shetty S, Khare M, Ghosh K. Placental histomorphology in unexplained foetal loss with thrombophilia. Indian J Med Res 2009;129:144-149.
5. Branch DW, Porter TF, Rittenhouse L, Caritis S, Sibai B, Hogg B, Lindheimer MD, et al.; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Antiphospholipid antibodies in women at risk for preeclampsia. Am J Obstet Gynecol 2001;184:825-32; discussion 832.
6. Mousa HA, Alfirevic Z. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome? Hum Reprod 2000;15:1830-1833. (Pubitemid 30636078)
7. Van Horn JT, Craven C, Ward K, Branch D W, Silver RM. Histologic features of placentas and abortion specimens from women with antiphospholipid and antiphospholipid-like syndromes. Placenta 2004;25:642-648. (Pubitemid 38950318)
8. Redline RW. Placental pathology: a systematic approach with clinical correlations. Placenta 2008;29 Suppl A:S86-S91.
9. Redline RW. Clinical and pathological umbilical cord abnormalities in fetal thrombotic vasculopathy. Hum Pathol 2004;35:1494-1498. (Pubitemid 40017989)
10. Khong TY, Hague WM. Biparental contribution to fetal thrombophilia in discordant twin intrauterine growth restriction. Am J Obstet Gynecol 2001;185:244-245. (Pubitemid 32681828)
11. Ariel I, Anteby E, Hamani Y, Redline RW. Placental pathology in fetal thrombophilia. Hum Pathol 2004;35:729-733. (Pubitemid 38881083)
12. Leistra-Leistra MJ, Timmer A, van Spronsen FJ, Geven WB, van der Meer J, Erwich JJ. Fetal thrombotic vasculopathy in the placenta: a thrombophilic connection between pregnancy complications and neonatal thrombosis? Placenta 2004;25 Suppl A:S102-S105. (Pubitemid 38514965)
13. Vern TZ, Alles AJ, Kowal-Vern A, Longtine J, Roberts DJ. Frequency of factor V(Leiden) and prothrombin G20210A in placentas and their relationship with placental lesions. Hum Pathol 2000;31:1036-1043.
14. Wintermark P, Boyd T, Parast MM, Van Marter LJ, Warfield SK, Robertson RL, Ringer SA. Fetal placental thrombosis and neonatal implications. Am J Perinatol 2010;27:251-256.
15. Arias F, Romero R, Joist H, Kraus FT. Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in the placenta. J Matern Fetal Med 1998;7:277-286.
16. Akar N, Akar E, Dalgin G, Sözüöz A, Omürlü K, Cin S. Frequency of Factor V (1691 G -> A) mutation in Turkish population. Thromb Haemost 1997;78:1527-1528.
17. Akar N, Misirlioglu M, Akar E, Avcu F, Yalçin A, Sözüöz A. Prothrombin gene 20210 G - A mutation in the Turkish population. Am J Hematol 1998;58:249. (Pubitemid 28303561)
18. Akar N, Akar E, Deda G, Sipahi T, Orsal A. Factor V1691 G-A, prothrombin 20210 G-A, and methylenetetrahydrofolate reductase 677 C-T variants in Turkish children with cerebral infarct. J Child Neurol 1999;14:749-751.